CELG

Celgene Corporation Press Releases

$87.83
*  
0.31
0.35%
Get CELG Alerts
*Delayed - data as of Jul. 10, 2014  -  Find a broker to begin trading CELG now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    CELG After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Celgene Reports Results from the Phase III POSTURE Study Evaluating Oral OTEZLA® in Ankylosing Spondylitis
7/9/2014 7:00:00 AM - Business Wire

Celgene Corporation to Announce Second Quarter 2014 Results on July 24, 2014
7/1/2014 8:30:00 AM - Business Wire

CORRECTING and REPLACING Celgene Corporation Mourns the Passing of Board of Director Member, Rodman L. Drake
6/26/2014 8:30:00 AM - Business Wire

Celgene Corporation Mourns the Passing of Board of Director Member, Rodman L. Drake
6/26/2014 8:30:00 AM - Business Wire

Celgene Stockholders Approve Two-for-One Stock Split
6/19/2014 8:30:00 AM - Business Wire

Retrospective Analysis of Overall Survival Adjusting for Patient Crossover in Phase III Study of POMALYST®/IMNOVID® (Pomalidomide) in Previously Treated Multiple Myeloma Presented at EHA
6/14/2014 12:30:00 PM - Business Wire

Results from Phase III Study (AML-001) of VIDAZA® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at EHA
6/14/2014 8:57:00 AM - Business Wire

Studies Presented at 19th European Hematology Association Annual Congress Evaluate Activin Receptor Ligand Trap Programs in Beta-Thalassemia
6/14/2014 3:00:00 AM - Business Wire

Analysis of Health-Related Quality of Life Measures from the MM-020/IFM 07-01 (FIRST®) Trial Presented at EHA Annual Congress
6/13/2014 5:44:00 PM - Business Wire

Oral OTEZLA® (Apremilast) Showed Long-Term Clinical Benefits in Patients with Active Psoriatic Arthritis
6/11/2014 7:30:00 AM - Business Wire

Oral OTEZLA® (Apremilast) Monotherapy Showed Long-Term Clinical Benefits in DMARD-Naïve Patients with Active Psoriatic Arthritis
6/11/2014 7:30:00 AM - Business Wire

Post-Hoc Analysis of Overall Survival in Phase III MPACT Study of Patients with Advanced Pancreatic Cancer Presented at ASCO 2014
6/1/2014 9:00:00 AM - Business Wire

Organizational Changes Strengthen and Expand Celgene Leadership Team
5/22/2014 6:00:00 AM - Business Wire

AADi Announces Licensing Agreement with Celgene for Nanotechnology-Based Drug Candidate
5/20/2014 9:00:00 AM - PR Newswire

Celgene Corporation to Present at Investor Conferences in June
5/20/2014 8:30:00 AM - Business Wire

Semi-Annual Changes to the NASDAQ OMX CRD Global Sustainability Index
5/19/2014 8:05:00 AM - GlobeNewswire

Celgene Announces Presentations of Investigational Studies in Solid Tumor and Blood Cancers at ASCO 2014
5/14/2014 5:19:00 PM - Business Wire

Celgene Prices $2.5 Billion of Senior Unsecured Notes
5/7/2014 7:30:00 AM - Business Wire

Technical Coverage on Biotech Stocks -- Research on Celgene, Cell Therapeutics, Geron, and BioMarin Pharma
5/6/2014 9:15:00 AM - PR Newswire

Celgene Announces Offering of Senior Unsecured Notes
5/6/2014 8:30:00 AM - Business Wire

Celgene Corporation to Present at Investor Conferences in May
4/25/2014 8:30:00 AM - Business Wire

Celgene Reports First Quarter 2014 Operating and Financial Results
4/24/2014 7:33:00 AM - Business Wire

Celgene Acquires Late-Stage Product for Crohn’s Disease and Other Gastrointestinal Disorders
4/24/2014 7:30:00 AM - Business Wire

Upcoming Earnings Announcements -- Research on Superior Energy Services, Celgene, Penn National Gaming, and PerkinElmer
4/22/2014 12:32:00 PM - PR Newswire

ReCept Pharmacy to Distribute Otezla® (apremilast): The First FDA Approved Oral Medication for the Treatment of Psoriatic Arthritis for Adults
4/14/2014 5:45:00 PM - PR Newswire

    • << first
    • < previous
    • 1
    • next >
    • last >>